OliX, Icure IPOs Test Korean Biotech Sentiment Amid Samsung Uncertainties
Executive Summary
OliX Pharmaceuticals and Icure are poised to be first biotech firms to launch IPOs this year amid uncertainties over ongoing accounting issues at Samsung BioLogics and possible tougher accounting reviews on IPO seekers.